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Abstract 
Introduction: Several lines of evidence point to an important role for BP1, an isoform of 
DLX4 homeobox gene, in breast carcinogenesis and progression. BRCA1 is a well-known 
p l a y e r   i n   t h e   e t i o l o g y   o f   b r e a s t   c a n c e r .  While familial breast cancer is often marked by BRCA1 
mutation and subsequent loss of heterozygosity, sporadic breast cancers exhibit reduced 
expression of wild type BRCA1, and loss of BRCA1 expression may result in tumor devel-
opment and progression.  
Methods: T h e   C i s t e r   a l g o r i t h m   a n d  G e n o m a t i x   p r o g r a m   w e r e   u s e d   t o   i d e n t i f y   p o t e n t i a l   B P 1  
binding sites in BRCA1 gene. Real-time  PCR,  Western  blot  and  immunohistochemistry 
a n a l y s i s   w e r e   p e r f o r m e d   t o   v e r i f y   t h e   e x p r e s s i o n   o f   B R C A 1   a n d   B P 1   i n   c e l l   l i n e s   a n d   b r e a s t  
cancer tissues. Double-strand e d   s i R N A   t r a n s f e c t i o n   w a s   c a r r i e d   o u t   f o r   s i l e n c i n g   B P 1   e x-
pression. ChIP and EMSA were used to confirm that BP1 specifically binds to BRCA1.  
Results: A   p u t a t i v e   B P 1   b i n d i n g   s i t e   w a s   i d e n t i f i e d   i n   t h e   f i r s t   i n t r o n   o f   B R C A 1 ,   w h i c h   w a s  
confirmed by chromatin immunoprecipiation and electrophoresis mobility shift assay. BP1 and 
BRCA1 expression were inversely correlated in breast cancer cell lines and tissues, suggesting 
that BP1 may suppress BRCA1 transcription through consensus sequence binding.  
Conclusions: BP1 homeoprotein represses BRCA1 expression through direct binding to its 
first intron, which is consistent with a previous study which identified a novel transcriptional 
repressor element located more than 500 base pairs into the first intron of BRCA1, suggesting 
that the first intron plays an important role in the negative regulation of BRCA1. Although 
f u r t h e r   f u n c t i o n a l   s t u d i e s   a r e   n e c e s s a r y   t o   c o n f i r m   i t s   r e p r e s s o r   a c t i v i t y   t o w a r d s   B R C A 1 ,   t h e  
elucidation of the role of BP1 in breast tumorigenesis holds great promise in establishing BP1 
as a novel target for drug therapy. 
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Introduction 
B r e a s t   c a n c e r   i s   t h e   s e c o n d   l e a d i n g   c a u s e   o f  
cancer  deaths  in  women  after  lung  cancer  and,  ex-
c l u d i n g   c a n c e r s   o f   t h e   s k i n ,   i s   t h e   m o s t   c o m m o n   f o r m  
of cancer among women. B r e a s t   c a n c e r   i s   o n e   o f   t h e  
most  common  malignancies  affecting  women  and 
approximately 207,090 new cases of invasive breast 
cancer are expected to be diagnosed as well as an es-
t i m a t e d   5 4 , 0 1 0   a d d i t i o n a l   c a s e s   o f   i n   s i t u   t u m o r   i n   t h e  
United States in 2010, and about 39,840 women are 
expected to die from the disease [1]. T h e   l o s s   o f   c e l lu-
lar regu l a t i o n   a s s o c i a t e d   w i t h   b r e a s t   c a n c e r   i s   a   m u l-
ti-step  process  that  involves  the  coordinated  activa-
tion or inhibition of specific intact or altered genes, 
often transcription factors that function as oncogenes 
or tumor suppressors. B R C A 1   i s   a   t u m o r   s u p p r e s s or 
g e n e   t h a t   i s   m u t a t e d   i n   u p   t o   4 5 %   o f   b r e a s t   c a n c e r   i n  
families with multiple cases of breast cancer [2]. Inhe-
r i t e d   m u t a t i o n s   i n   t h e   B R C A 1   g e n e   a r e   c o r r e l a t e d   w i t h  
a n   i n c r e a s e d   p r o b a b i l i t y   o f   b r e a s t   o r   o v a r i a n   c a n c e r ,  
and the normal allele is frequently removed by loss of 
heterozygosity [3] [4]. In sporadic breast cancer, the 
i n c i d e n c e   o f   B R C A 1   m u t a t i o n   i s   v e r y   l o w  [5]. How-
e v e r ,   r e d u c e d   l e v e l s   o f   B R C A 1   p r o t e i n   a n d   m R N A  
expression  are  often  observed,  suggesting  that  re-
pression of BRCA1 is involved rather than mutations 
[6] [7]. This hypothesis was supported by experiments 
in which the int r o d u c t i o n   o f   a   n o r m a l   B R C A 1   g e n e  
inhibited the growth of breast and ovarian cancer cell 
lines in vitro and inhibited the tumor growth rate of 
M C F 7   b r e a s t   c a n c e r   c e l l s   i n   n u d e   m i c e   [8].  Growth 
in h i b i t i o n   w a s   n o t   o b s e r v e d   i n   c o l o n   a n d   l u n g   c a n c e r  
cell lines, further demonstrating that loss of BRCA1 
activity  plays  a  special  role  in  breast  and  ovarian 
cancers and not other types of cancer. 
Other  mechanisms  have  been  proposed  for 
BRCA1 inactivation in sporadic cancer including ep-
igenetic  silencing.  Hypermethylation  of  the  BRCA1 
p r o m o t e r   r e g i o n   C p G   i s l a n d   w a s   f i r s t   r e p o r t e d   i n   t w o  
o u t   o f   s e v e n   b r e a s t   t u m o r s   a n d   l a t e r   i n   t w o   o u t   o f   s i x  
b r e a s t   t u m o r s   a n d   t w o   o u t   o f   f i v e   o v a r i a n   t u m o r s  [9] 
[10].  A  larger  study  by  Catteau  et  al.  found  that 
B R C A 1   p r o m o t e r   i s   h i g h l y   m e t h y l a t e d   i n   1 1 %   o f  
breast carcinomas and 5% of ovarian carcinomas [11]. 
H y p e r m e t h y l a t i o n ,   t h e r e f o r e ,   a p p e a r s   t o   n o t   b e   a   s i g-
nificant mechanism for repression of BRCA1 expres-
s i o n   i n   b r e a s t   t u m o r s .   Additional  studies  have  fo-
cused  on  other  transcriptional  and/or 
post-transcriptional  mechanisms  by  which  BRCA1 
inactivation is achieved in breast and ovarian cancer. 
Baldassarre  et  al.  found  that  the  HMGA1b  protein 
b i n d s   d i r e c t l y   t o   t h e   B R C A 1   p r o m o t e r   a n d   r e p r e s s e s  
BRCA1 transcription both in vitro and in vivo [12]. In 
a n o t h e r   s t u d y ,   c y c l i n   D 1   e x p r e s s i o n   w a s   f o u n d   t o  
antagonize BRCA1 inhibition of estrogen receptor α 
(ERα)-dependent gene expression [13]. 
B R C A 1   h a s   b e e n   h y p o t h e s i z e d   t o   p l a y   a   r o l e   i n  
DNA damage repair, and many studies have reported 
a   r e d u c t i o n   i n   B R C A 1   m R N A   a n d   p r o t e i n   l e v e l s   f o l-
l o w i n g   e x t e n d e d   e x p o s u r e   t o   D N A   d a m a g i n g   a g e n t s  
[14] [15] [16]. I n   o n e   s t u d y ,   r e p r e s s i o n   o f   p 5 3   b y   h u-
man papilloma virus  E6  resulted  in an inability  to 
d o w n r e g u l a t e   B R C A 1   i n   r e s p o n s e   t o   t h e  
DNA-damaging agent adriamycin, while ectopic ex-
p r e s s i o n   o f   p 5 3   r e s u l t e d   i n   t h e   r a p i d   d o w n r e g u l a t i o n  
o f   B R C A 1   m R N A   a n d   p r o t e i n   l e v e l s  [17]. These re-
sults, in conjunction with others, suggest a feedback 
loop where BRCA1 initially induces p53 expression 
and p53 later acts to negatively regulate BRCA1. The 
p r e c i s e   m e c h a n i s m   o f   B R C A 1 -mediated  growth  reg-
ulation  and  tumor  suppression,  however,  remains 
elusive. There is increasing evidence, however, that 
s u g g e s t s   B R C A 1   f u n c t i o n s   a s   a   r e g u l a t o r   o f   c e n t r o-
some number. B R C A 1   i s   l o c a l i z e d   t o   t h e   c e n t r o s o m e  
in mitotic cells [18] [19], and interference with BRCA1 
f u n c t i o n   b y   v a r i o u s   m e t h o d s   r e s u l t s   i n   a n   i n c r e a s e   i n  
centrosome number. In one study, mouse fibroblasts 
d e r i v e d   f r o m   e x o n   1 1   k n o c k o u t s   w e r e   f o u n d   t o   h a v e  
amplified centrosomes [20]. Amino acid residues 504 
to 803 of BRCA1 bind γ-tubulin, a major component of 
centrosomes,  and  stable  overexpression  of  the 
γ-tubulin  binding  domain  results  in  increased  cen-
trosome  number  in  tissue  culture  cells  [21].  Acute 
expression  of  an  inhibitor  peptide  that  binds  to  the 
c a r b o x y   t e r m i n u s   o f   B R C A 1   c a u s e s   r a p i d   c e n t r o s o m e  
amplification in a mammary cell line [22]. I n   a   s t u d y  
by  Starita  et  al.,  transient  inhibition  of  BRCA1  in 
mammary  tissue-derived cell lines caused rapid ac-
cumulation  and  fragmentation  of  centrosomes  [23]. 
BRCA1 inhibition in nonmammary cell lines, howev-
er, did not result in centrosome amplification. 
B P 1 ,   a   D L X 4   i s o f o r m ,   b e l o n g s   t o   t h e   h o m e o b o x  
f a m i l y   o f   m a s t e r   r e g u l a t o r y   g e n e s ,   w h i c h   a r e   i m p l i-
cated  in  early  development  and  cell  differentiation 
and  are  frequently  dysregulated  in  cancer  [24].  In 
normal erythroid cells, BP1 acts as a putative repres-
s o r   o f   t h e   β-globin gene [25] [26]. BP1 was expressed 
in 47% of the adult and 81% of the pediatric acute 
myeloid leukemia patients, and BP1 overexpression 
increased the leukemogenic potential of K562 cells in 
vitro  [27].  Furthermore,  molecular  analysis  revealed 
t h a t   B P 1   e x p r e s s i o n   i s   r e q u i r ed for cell survival in 
K562  cells,  implicating  BP1  in  an  anti-apoptotic 
pathway  [28].  BP1  was  mapped  to  chromosome 
17q21-22 ,   a   r e g i o n   o f   D N A   t h a t   i s   f r e q u e n t l y   a m p l i f i e d  Int. J. Biol. Sci. 2010, 6 
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in breast cancer and contains BRCA1 and oncogene 
erbB2  [26].  S i n c e   B P 1   m a y   b e   i n v o l v e d   i n   a n   a n-
ti-apoptotic pathway, it was speculated that aberrant 
e x p r e s s i o n   o f   B P 1   m i g h t   a l s o   p r o m o t e   i n c r e a s e d   c e l l  
survival and growth in other malignancies including 
breast cancer. BP1 mRNA levels were analyzed in a 
s e r i e s   o f   b r e a s t   c a n c e r   c e l l   l i n e s   u s i n g   R T -PCR, and a 
correlation  was  found  between  BP1  expression  and 
tumorigenesis in mice [29]. Cell lines that express little 
or no BP1 (Hs578T, MDA-MB-435S, and MCF10A) are 
n o t   t u m o r i g e n i c ,   w h e r e a s   c e l l s   t h a t   e x p r e s s   h i g h   l e v e l s  
of  BP1  (MCF7-ADR,  MDA-MB-468,  and 
MDA-MB-231) are tumorigenic. In the analysis of 46 
invasive ductal breast tumors by Fu et al.,  BP1  ex-
pression wa s   d e t e c t a b l e   i n   8 0 %   o f   t h e m   a s   m e a s u r e d  
by RT-P C R ,   c o m p a r e d   w i t h   a   l a c k   o f   e x p r e s s i o n   i n   s i x  
normal breast tissues and low level expression in one 
normal breast tissue [29]. A correlation was also found 
in these studies between BP1 expression and estrogen 
re c e p t o r   ( E R )   s t a t u s   a s   w e l l   a s   b e t w e e n   B P 1   e x p r e s-
sion and race. BP1 expression was significantly higher 
i n   E R   n e g a t i v e   ( 1 0 0 % )   v e r s u s   E R   p o s i t i v e   ( 7 3 % )   t u-
m o r s   a n d   i n   t h e   t u m o r s   o f   A f r i c a n -American women 
(89%) versus those of Caucasian women (57%). These 
findings have important scientific and clinical impli-
cations. Since ER negative tumors are clinically more 
a g g r e s s i v e   a n d   h a v e   a   p o o r e r   p r o g n o s i s   c o m p a r e d   t o  
ER positive tumors, the expression of BP1 might serve 
a s   a   r e l i a b l e   m a r k e r   o f   b r e a s t   t u m o r   a g g r e s s i v e ness 
[30]. Th i s   w a s   s u p p o r t e d   b y   o u r   r e c e n t   s t u d y   d e m o n-
strating that BP1 enhances cell proliferation and me-
tastatic potential in ER negative Hs578T breast cancer 
cells  [31].  Furthermore,  the  oncogenic  properties  of 
B P 1   a s   r e v e a l e d   i n   t h e   l e u k e m i a   s t u d y   s u g g e s t   t h a t   t h e  
high percentage (80%) of BP1 expression in invasive 
ductal  carcinomas  contributes  to  enhanced  breast 
t u m o r   g r o w t h   r a t e   a n d   i n v a s i v e n e s s .  We also found 
t h a t   t h e   p r e v a l e n c e   o f   B P 1   p o s i t i v e   c e l l s   a n d   t h e   i n-
tensity  of  BP1  immunostaining  increased  with  the 
extent  of  ductal  proliferation  and  carcinogenesis. In 
addition, BP1 positive cells were observed to have a 
substantially  higher  proliferation  rate  compared  to 
morphologically similar BP1 negative cells, and BP1 
co-localized with onco-protein erbB2 in 15 in situ and 
infiltrating  breast  ductal  carcinomas  [32].  We  have 
also  identified  a  number  of  potential  direct  BP1 
binding targets, including VEGFA, STAT1, ITGA9, etc 
[33]. BP1 has been shown, therefore, to have a prom-
inent role in breast cancer progression and invasion. 
However, the precise nature of its role in carcinoge-
nesis remains unclear. In  this  study,  we  investigate 
t h e   r o l e   o f   B P 1   i n   b r e a s t   t u m o r i g e n e s i s ,   a n d   e v i d e n c e  
w i l l   b e   p r e s e n t e d   s h o w i n g   h o w   B P 1   f u n c t i o n s   a s   a  
transcriptional repressor of BRCA1 in breast cancer. 
Materials and Methods 
Cister algorithm (Cis-element  Cluster  Finder) 
and Genomatix program. GenBank accession number 
U37574 for human BRCA1 gene, partial coding se-
q u e n c e   w a s   i n p u t   i n t o   t h e   C i s t e r   s e a r c h   f o r m   ( B o s t o n  
University)  to  predict  regulatory  regions  in  the 
BRCA1 promoter region. A  user-defined cis-element 
was entered as a TRANSFAC-s t y l e   m a t r i x   f o r   t h e   B P 1  
consensus  binding  sequence 
(A/T)T(A/C)(A/T)ATATG (25). The motif probabil-
ity threshold was set at 0.01. Genomatix program was 
also  used  to  predict  all  potential  BP1  homeoprotein 
binding sites in BRCA1. 
Cell lines and cell culture. MCF7 breast cancer 
c e l l s   s t a b l y   t r a n s f e c t e d   w i t h   t h e   p c D N A 3 . 2 / B P 1   c o n-
struct or an empty vector were maintained in RPMI 
1640 media (Invitrogen) medium with 10% fetal bo-
vine serum plus 500ug/ml of Geneticin (Invitrogen) 
and 1% penicillin/ streptomycin. BT-20, SKBR3 breast 
cancer  cells  were  transiently  transfected  with  the 
p c D N A 3 . 2 / B P 1   c o n s t r u c t   o r   a n   e m p t y   v e c t o r   a n d  
maintained  in  Eagle's  Minimum  Essential  Medium 
(ATCC) and McCoy's 5a Medium Modified (ATCC), 
respectively,  with  10%  fetal   b o v i n e   s e r u m   p l u s  
500ug/ml  of  Geneticin  (Invitrogen)  and  1%  penicil-
lin/ streptomycin. H s 5 7 8 T   b r e a s t   c a n c e r   c e l l s   s t a b l y  
transfected  with  the  pcDNA3.2/BP1  construct  or  an 
e m p t y   v e c t o r   w e r e   m a i n t a i n e d   i n   D M E M   c o n t a i n i n g  
high glucose, L-glutamine, and sodium  pyruvate  (In-
vitrogen) with 10% fetal bovine serum plus 500ug/ml 
of G418 [33].  
siRNA  synthesis  and  transfection. 
Double-stranded  siRNA  targeting  BP1  was  synthe-
sized using Silencer® siRNA Construction Kit (Am-
bion). Template oligonucleotides for siRNA synthesis 
were selected using BP1 (DLX4 Variant 1) accession 
n u m b e r   N M _ 1 3 8 2 8 1   b y   s i D i r e c t   ( U n i v e r s i t y   o f   T o k y o ,  
http://design.rnai.jp/).  Two  target  sequences  were 
selected.  An  eight  nucleotide  sequence, 
5’-CCTGTCTC-3 ’ ,   w a s   a d d e d   t o   t h e   3 ’   e n d   o f   t h e   t a r-
g e t   s e q u e n c e s ,   a s   i n s t r u c t e d   b y   S i l e n c e r   p r o t o c o l .   T w o  
target  sequences  are  the  following.  T1,  sense:  5’- 
GACCTATGGGTAATTTATGCTCCTGTCTC-3’,  an-
ti-sense:  5’-AAAGCATAAATTACCCATAGGCCTG 
TCTC-3’;  T2,  sense:  5’-  AAGGAAC 
TGTGCAGATTTAGACCTGTCTC-3’,  anti-sense:  5’- 
GTTCTAAATCTGCACAGTTCCCCTGTCTC-3’.  The 
designed sequences were synthesized  by  Integrated 
DNA  Technologies  (IDT).  Double-stranded  siRNA 
was then synthesized according to the Silencer pro-
tocol, and quantified using the Nanodrop spectrome-
ter  (Thermo  Scientific).  T47D,  MDA-MB-231  cells 
were  seeded  into  two  six-well plates with 2.5 x105 Int. J. Biol. Sci. 2010, 6 
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cells/well and grown in 2mL RPMI-1640 (Invitrogen), 
Leibovitz's L-15  Medium  (ATCC)  respectively,  sup-
plemented with 10% fetal bovine serum. After a con-
fluence of 60-70% in each well was reached, the cells 
were then transfected with T1, T2, Non-targeting Pool 
s i R N A   ( T h e r m o   S c i e n t i f i c )   a n d   n o   s i R N A   c o n t r o l   u s-
i n g   F u G E N E ®   H D   T r a n s f e c t i o n   R e a g e n t   ( R o c h e   A p-
plied Science). The transfection complexes were pre-
pared with 1 µg of siRNA, 200µl of plain medium and 
2 µ l   o f   F u G E N E e n e   R e a g e n t .   T h e   c o m p l e x e s   w e r e   a p-
plied  according  to  the  manufacturers’  instructions. 
After 48h, the transfected cells were collected for ve-
rification of BP1 knockdown and analysis of knock-
down effects.  
Chromatin  immunoprecipitation  assay.  1.5  x 
106 BP1-o v e r e x p r e s s i n g   M C F 7   o r   H s 5 7 8 T   c e l l s   w e r e  
crosslinked  in  either  50  mL  RPMI  1640  media  or 
D M E M   w i t h   1 %   f o r m a l d e h y d e   f o r   t e n   m i n u t e s   a t  
37ºC.  Cells  were  pelleted  by  centrifugation  and 
w a s h e d   t w i c e   w i t h   c o l d   P B S ,   r e s u s p e n d e d   i n   S D S   l y s i s  
buffer containing Complete, Mini protease inhibitors 
( R o c h e ) ,   a n d   i n c u b a t e d   f o r   t e n   m i n u t e s   o n   i c e .  Chro-
matin was sheared on ice to an average size of 200-500 
b a s e   p a i r s   a n d   d i l u t e d   1 0   f o l d   w i t h   C h I P   dilution 
buffer containing Complete, Mini Protease inhibitors. 
T h e   l y s a t e   w a s   p r e c l e a r e d   w i t h   s a l m o n   s p e r m   D N A  
(Stratagene)/Protein  G  PLUS/Protein  A-Agarose 
b e a d s   ( C a l b i o c h e m )   f o r   o n e   h o u r   a t   4 º C   w i t h   c o n s t a n t  
rotation. The beads were pelleted, 10% of the super-
n a t a n t   w a s   r e m o v e d   f o r   i n p u t ,   a n d   e q u a l   v o l u m e s   o f  
the remaining supernatant were incubated overnight 
at 4ºC with constant rotation using 10 μg of BP1 po-
lyclonal antibody (Research Genetics) or no antibody 
for  control.  Samples  were  incubated  with  60  μL  of 
s a l m o n   s p e r m   D N A / P r o t e i n   G   P L U S / P r o t e i n   A  
a g a r o s e   b e a d s   f o r   t w o   h o u r s   a t   4 º C   w i t h   c o n s t a n t   r o-
tation.  Beads  were  collected  by  centrifugation  and 
w a s h e d   o n c e   w i t h   1   m L   l o w   s a l t   b u f f e r ,   t w i c e   w i t h   1  
m L   h i g h   s a l t   b u f f e r ,   o n c e   w i t h   1   m L   L i C l   w a s h   b u f f e r ,  
a n d   o n c e   w i t h   1   m L   T r i s -EDTA  buffer.  Chromatin 
w a s   e l u t e d   t w i c e   i n   2 5 0   μ L   o f   f r e s h l y   m a d e   e l u t i o n  
buffer at room temperature with constant rotation for 
15 minutes. For reverse crosslinking, the eluate and 
i n p u t   c h r o m a t i n   w e r e   i n c u b a t e d   w i t h   2 0   μ L   5   M   N a C l  
f o r   f o u r   h o u r s   a t   6 5 º C ,   t h e n   s t o r e d   o v e r n i g h t   a t   -20ºC. 
P r o t e i n s   w e r e   d e g r a d e d   b y   i n c u b a t i o n   w i t h   1 0 0  
μ g / m L   p r o t e i n a s e   K   f o r   o n e   h o u r   a t   5 6 º C .  DNA  was 
purified  twice  by  phenol/chloroform/  isoamyl 
(25:24:1) extraction and precipitated in 1 mL absolute 
ethanol with 50 μL 3 M sodium acetate at -80ºC for 
thirty minutes. The precipitated DNA was pelleted by 
centrifugation  and  washed  with  70%  ethanol.  After 
w a s h i n g ,   t h e   D N A   w a s   p e l l e t e d   a g a i n ,   a l l o w e d   t o  
air-dry, and resuspended in Tris-EDTA buffer for use 
in PCR. 
PCR  assays. PCR reactions for amplification of 
chromatin immunoprecipitates and input DNA were 
p e r f o r m e d   i n   a   t o t a l   v o l u m e   o f   2 5   μ L   u s i n g   T a q   D N A  
Polymerase  (Invitrogen)  following  manufacturer’s 
protocol. DNA was initially denatured at 94ºC for 2 
minutes, followed by 28 cycles of denaturation at 94ºC 
for 45 seconds, annealing at 58ºC for 45 seconds, and 
elongation at 72ºC for 45 seconds, and a final cycle of 
94ºC for 45 seconds, 58ºC for 45 seconds, and 72ºC for 
7  minutes. P r i m e r s   w e r e   d e s i g n e d   t o   f l a n k   t he puta-
tive  BP1  binding  site  in  the  first  intron  of  BRCA1 
(Forward:  5’-GGACGTTGTCATTAGTTCTTTGG-3’; 
Reverse: 5’-CGCGAAGAGCAGATAAATCC-3’). PCR 
products were run on a 2% agarose gel and visualized 
o n   a   K o d a k   I m a g e   S t a t i o n   2 0 0 0 M M   w i t h   K o d a k   1 D  
version 6 software. 
Electrophoretic  mobility  shift  assay.  Electro-
p h o r e t i c   m o b i l i t y   s h i f t   a s s a y   ( E M S A )   w a s   p e r f o r m e d  
u s i n g   t h e   D I G   G e l   S h i f t   K i t ,   2 nd Generation (Roche) for 
nonradioactive  detection  of  sequence  specific  DNA 
binding  proteins  following  the  manufacturer’s  pro-
tocol. Briefly,  a  33- base pair double-stranded  oligo-
n u c l e o t i d e   p r o b e   s p e c i f i c   f o r   B P 1   b i n d i n g   w a s  
3’-end-labeled  using  Digoxigenin-11-ddUTP 
(DIG-11-ddUTP) and terminal transferase. Whole cell 
extracts  from  MCF7  BP1  overexpressing  cells  were 
incubated with the labeled probe in binding buffer (20 
mM  HEPES–KOH  (pH  7.6),  1  mM  EDTA,  10  mM 
(NH4)2SO4, 1 mM DTT, 0.2% (w/v) Tween 20, and 30 
m M   K C l )   c o n t a i n i n g   1   µ g   p o l y   d [ I -C ]   a n d   0 . 1   µ g   p o l y  
L-lysine in a final volume of 20 µL for 15 minutes at 
room  temperature.  For  gel-shift  competition,  unla-
beled  specific  competitor  (50-  or  100-fold  molar 
excess) or a non-competitive negative control (25-fold 
m o l a r   e x c e s s )   w a s   i n c l u d e d   i n   t h e   r e a c t i o n .  Sequences 
o f   p r o b e s   w e r e   a s   f o l l o w s :   BP1  binding  (Forward: 
5’-TTAAAAAGATATATATATATGTTTTTCTAATG
T-3’;  Reverse:  5’-ACATTAGAAAAACATATATAT 
ATATCTTTTTAA-3’) and negative control (Forward: 
5’-TCTTAGAGGGAGGGCTGAGGGTTTGAAGTCC
AACTCCTAAGCC-3’;  Reverse:  5’-AGAATCTCCC 
TCCCGACTCCCAAACTTCAGGTTGAGGATTCGG-
3’.  DNA-protein  complexes  were  resolved  using  a 
pre-run  6%  polyacrylamide  non-denaturing  gel  in 
0.5% TBE and transferred to a nylon membrane. The 
o l i g o s   w e r e   f i x e d   b y   U V   c r o s s -linking  and  the 
DIG-labeled probe was visualized by chemilumines-
cence. 
RNA extraction and Real-time RT-PCR assays. 
Total  RNA  was extracted from human breast cancer 
cell lines with Trizol reagent (Invitrogen) according to 
the  manufacturer’s  protocol.  cDNA  synthesis  was Int. J. Biol. Sci. 2010, 6 
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c a r r i e d   o u t   w i t h   1   μ g   o f   t o t a l   R N A   u s i n g   t h e  
First-Strand  cDNA  Synthesis  Kit  (Invitrogen).  Tem-
plates for real-time PCR standards were prepared by 
a m p l i f i c a t i o n   o f   t h e   t a r g e t   g e n e s   u s i n g   c D N A   i n   a  
t o t a l   v o l u m e   o f   2 5   μ L   u s i n g   T a q   D N A   P o l y m e r a s e  
(Invitrogen)  following  the  manufacturer’s  protocol. 
Specifically,  PCR  was  performed  at  the  following 
conditions: denaturing at 94ºC for 2 minutes, followed 
b y   2 8   c y c l e s   o f   d e n a t u r a t i o n   a t   9 4 º C   f o r   4 5   s e c o n d s ,  
annealing at 60ºC for 45 seconds, and elongation at 
72ºC  for 45 seconds,  with  an  additional  elongation 
step  at  72ºC  for  5  minutes.  The  primers  used  were 
specif i c   f o r   B P 1   ( F orward: 
5’-CAAAGCTGTCTTCCCAGACC-3’;  Reverse: 
5’-GTTGTAGGGGACAAGCCAAG-3’),  BRCA1 
(Forward  5’-TGTGAGGCACCTGTGGTGA-3’;  Re-
verse: 5’-CAGCTCCTGGCACTGGTAGAG-3’), or 18S 
(Forward  5’-CCGCAGCTAGGAATAAT 
GGA-3’;  Reverse:  5’-CCCTCTTAATCATGGCCT 
CA-3’). Real-time  PCR  standards  comprised a series 
o f   5   d i l u t i o n s   o f   t h e   r e s p e c t i v e   P C R   p r o d u c t   a t   1 ,   1 : 1 0 ,  
1:100, 1:1,000, and 1:10,000 for relative quantitation of 
target expression levels. 
Real-t i m e   P C R   r e a c t i o n s   w i t h   t h e   a b o v e   p r i m e r s  
were performed in a total volume of 25 μL using Pla-
t i n u m   S Y B R   G r e e n   q P C R   S u p e r M i x   U D G   w i t h   R O X  
(Invitrogen) according to the manufacturer’s protocol. 
T h e r m o c y c l i n g   w a s   p e r f o r m e d   u s i n g   a   7 3 0 0   R e a l   T i m e  
PCR System (Applied Biosystems) with the following 
c o n d i t i o n s :   1   c y c l e   o f   5 0 º C   f o r   2   m i n u t e s ,   1   c ycle  of 
9 5 º C   f o r   1 0   m i n u t e s ,   4 0   c y c l e s   o f   9 5 º C   f o r   1 5   s e c o n d s  
a n d   6 0 º C   f o r   1   m i n u t e ,   a n d   a   f i n a l   c y c l e   o f   9 5 º C   f o r   1 5  
seconds, 60ºC for 30 seconds, and 95ºC for 15 seconds. 
Data was analyzed using 7300 System Sequence De-
tection  Software  version  1.2  (Applied  Biosystems). 
The relative expression levels of BP1 and BRCA1 were 
c a l c u l a t e d   u s i n g   t h e   d e l t a   C t   v a l u e   a n d   n o r m a l i z e d  
against ribosomal 18S expression. 
Protein  extraction  and  Western  blot  analysis. 
Proteins were extracted from cell lines using T-PER 
Tissue Protein Extraction Reagent (Pierce) according 
to the manufacturer’s protocol. Complete, Mini Pro-
t e a s e   I n h i b i t o r   C o c k t a i l   ( R o c h e )   w a s   a d d e d   t o   t h e   e x-
traction solution prior to lysis to prevent proteolytic 
activity. Cell protein lysate was prepared with SDS 
gel-loading buffer containing β-mercaptoethanol and 
heated at 98ºC for 15 minutes.  Proteins  were  sepa-
r a t e d   b y   S D S -P A G E   u s i n g   a   1 2 %   R e a d y   G e l   T r i s -HCl 
pre-cast polyacrylamide gel (Bio-Rad) and transferred 
overnight.  T h e   m e m b r a n e   w a s   b l o c k e d   p r i o r   t o   t h e  
addition  of  the  primary  antibody  with  5%  milk  in 
Tris/NaCl/EDTA  (TNE)  with  0.05%  Tween.  The 
membrane was incubated overnight with either BP1 
(NB 100-481) rabbit polyclonal antibody (Novus Bio-
logicals)   a t   a   d i l u t i o n   o f   1 : 5 , 0 0 0   i n   T N E   b u f f e r   w i t h  
0.05%  Tween,  BRCA1  monoclonal  antibody  (Cat# 
NB100-598) (Novus Biologicals), which recognizes the 
epitope amino acid 1314-1600, at a dilution of 1:500 in 
TNE buffer with 0.05% Tween and 5% milk, or β-actin 
(A  5441)  mouse  monoclonal  antibody  (Sigma)  at  a 
dilution of 1:1 0 , 0 0 0   i n   T N E   b u f f e r   w i t h   0 . 0 5 %   T w e e n .  
T h e   m e m b r a n e   w a s   w a s h e d   3   t i m e s   w i t h   T N E / 0 . 0 5 %  
Tween  and  incubated  with  a  goat-anti-rabbit  IgG 
c o n j u g a t e d   t o   h o r s e   r a d i s h   p e r o x i d a s e   ( S a n t a   C r u z )  
for  BP1  or  a  goat-anti-mouse  IgG  (Amersham)  for 
BRCA1  and  β-actin  at  a  1:10,000  dilution  in 
TNE/0.05%  Tween  (and  5%  milk  for  BRCA1).  En-
hanced  chemiluminescence  with  Western  Blotting 
Luminol Reagent (Santa Cruz) was used according to 
the manufacturer’s protocol to visualize proteins and 
quantify band intensity. 
Immunhistochemistry  assays  (IHC).  Consecu-
tive  tissue sections  at 8-1 0   μ m   t h i c k n e s s   w e r e   m a d e  
f r o m   f r e s h   f r o z e n   h u m a n   b r e a s t   t u m o r s   ( n = 1 5 )   w i t h  
co-existing  normal,  pre-invasive,  and  invasive  com-
ponents. Sections were placed on positively charged 
microscopic slides and fixed in 10% buffered formalin 
f o r   1 0   m i n u t e s   a t   r o o m   t e m p e r a t u r e .  Next,  sections 
w e r e   w a s h e d   w i t h   P B S   ( p H   7 . 0 )   c o n t a i n i n g   0 . 2 %  
T w e e n   2 0   t h r e e   t i m e s   e a c h   f o r   1 0 -15 minutes at room 
t e m p e r a t u r e   a n d   s u b j e c t e d   t o   m o r p h o l o g i c a l   a n d  
immunohistochemical  assessment  using  previously 
published criteria and protocols [32].  
To  assess  the  potential  correlation  between 
B R C A 1   a n d   B P 1   e x p r e s s i o n ,   s e t s   o f   t w o   i m m e d i a t e  
adjacent sections from each case were immunostained 
with  affinity  purified  rabbit  polyclonal  antibodies 
raised against a peptide mapping at the C-terminus of 
human BRCA1 (I-20) (Cat# sc-646) (Santa Cruz) and 
a g a i n s t   a   p e p t i d e   m a p p i n g   a t   t h e   N -t e r m i n u s   o f   B P 1  
o f   h u m a n   o r i g i n   ( R e s e a r c h   G e n e t i c s ) .  Immunostaining 
w a s   c a r r i e d   o u t   u s i n g   p r e v i o u s l y   p u b l i s h e d   p r o t o c o l s  
[34]  [35].  Briefly,  sections  were  incubated  with  the 
primary antibody and different control solutions, in-
cluding  the  substitution  of  pre-i m m u n e   I g G   f o r   t h e  
p r i m a r y   a n t i b o d y ,   s u b s t i t u t i o n   o f   P B S   f o r   t h e   p r i m a r y  
or  secondary  antibody,  and  pre-absorption  of  the 
primary  antibody  with  the  corresponding  peptide 
(done only for BP1), overnight at room temperature. 
After the incubation, sections were washed with PBS 
containing  0.2%  Tween  20  three  times  each  for  5-7 
minutes. The  antigen/antibody  complexes  were  de-
tected  u s i n g   a n   A B C   d e t e c t i o n   k i t   ( V e c t o r )   a n d   a n  
AP-r e d   c h r o m o g e n   k i t   ( Z y m e d )   a c c o r d i n g   t o   t h e  
manufacturers’ protocols.  
T h e   e x p r e s s i o n   s t a t u s   o f   B P 1   a n d   B R C A 1   a t   t h e  
same  cell  population  in  two  different  sections  was 
compared. A given cell was considered to be positive Int. J. Biol. Sci. 2010, 6 
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i f   d i s t i n c t   c h r o m o g e n   c o l o r a t i o n   w a s   s e e n   i n   a l l   t h r e e  
duplicated procedures and no chromogen coloration 
was seen in any of the controls. 
Results 
Identification of potential BP1 homeoprotein 
binding sites in BRCA1.  
Analysis  of  a  partial  coding  sequence  of  the 
human  BRCA1  gene  (GenBank  accession  U37574) 
u s i n g   t h e   C i s t e r   a l g o r i t h m   a n d   G e n o m a t i x   p r o g r a m  
identified  21  putative  BP1  binding  sites 
(ATATATATG) within the first intron. We focused on 
the one with strongest potential from nucleotide po-
sitions  2,830  to  2,838,  which  is  -47  to  -39  base  pairs 
upstream of the translational start site, suggesting that 
BP1 might transcriptionally suppress BRCA1 through 
b i n d i n g   d o w n s t r e a m   o f   i t s   p r o m o t e r   ( F i g .   1 A, Fig. 6). 
T h e   p a r t i a l   c o d i n g   s e q u e n c e   i s   3 , 7 9 8   n u c l e otides long 
and includes the promoter and 5’ UTR, which consists 
of exons 1a and 1b as well as exon 2.  
 
Figure 1. Cister search results and PCR amplification of ChIP DNA samples from MCF7 and Hs578T cells. 
A. Cister predicts regulatory regions in DNA sequences by searching for clusters of cis-elements. The red line adjacent to 
the pink protein coding region corresponds to the putative BP1 binding site located on the positive strand of the human 
BRCA1 gene and indicates the probability that a regulatory factor binds at this position. B .   C h I P   a s s a y s   w e r e   c o n d u c t e d   w i t h  
a BP1 antibody and a no antibody control. A 186 base pair PCR fragment was amplified with BP1 immunoprecipitated and 
i n p u t   D N A   f r o m   B P 1   o v e r e x p r e s s i n g   M C F 7   a n d   Hs578T cells, but not with the no antibody control, using primers flanking 
the putative BP1 binding site. C. Correlation of BP1 mRNA expression with the level of ChIPed BRCA1 genomic DNA 
a n a l y s i s .   C h I P   a s s a y s   w e r e   p e r f o r m e d   o n   a   s e r i e s   o f   M C F 7   c e l l   l i n e s   w ith different levels of BP1 expression. Various levels of 
B R C A 1   g e n o m i c   D N A   w e r e   a m p l i f i e d   f r o m   t h e   C h I P   D N A   b y   S Y B R   r e a l -time PCR, in correlation with the mRNA ex-
pression of BP1 in each cell line. 
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Confirmation of BP1 binding t o   t h e   f i r s t   i n t r o n   o f  
BRCA1. 
Based  on  the  sequence  analysis,  primers  were 
d e s i g n e d   f l a n k i n g   t h e   p u t a t i v e   B P 1   b i n d i n g   s i t e   t o   b e  
used in PCR analysis of immunoprecipitates isolated 
by ChIP. To determine whether BP1 binds to the put-
ative consensus sequence identified by Cister, ChIP 
was performed with BP1 overexpressing MCF7 and 
Hs578T  cell  lines.  Chromatin  immunoprecipitates 
w e r e   a n a l y z e d   b y   P C R   a n d   a   1 8 6   b a s e   p a i r   p r o d u c t  
was  amplified  from  BP1  immunoprecipitated  chro-
m a t i n   b u t   n o   p r o d u c t   w a s   f o r m e d   f r o m   t he no anti-
body control for both cell lines analyzed (Fig. 1B). To 
evaluate  the  binding  efficiency,  we  performed  the 
ChIP on cell lines overexpressing BP1 and their con-
t r o l s   f o r   b o t h   M C F 7   a n d   H s 5 7 8 T   c e l l s .   T h e   r e a l -time 
P C R   d a t a   s h o w e d   t h a t   t h e   a m o u n t   o f   p u lled-down 
c o m p l e x   w a s   c o r r e l a t e d   w i t h   t h e   l e v e l   o f   B P 1   e x p r e s-
sion in those cells (Fig. 1C).  
 
Figure  2.  Electrophoretic  mobility  shift  assay 
(EMSA). Protein extract isolated from BP1 overexpressing 
MCF7  cells  binds  specifically  to  a  33-  nucleotide 
double-stranded  sequence  containing  the  putative  BP1 
binding site in the first intron of BRCA1. Labeled probe 
specific for the BP1 binding site was used in the binding 
reactions with the following additions: Lane 1, free probe; 
lane 2, protein extract; lane 3, protein extract plus 50-fold 
molar  excess  of  unlabeled  BP1  specific  double-stranded 
probe; lane 4, protein extract plus 100-f o l d   m o l a r   e x c e s s   o f  
unlabeled  BP1  specific  double-stranded  probe;  lane  5, 
protein extract plus 100-fold  molar  excess  of  unlabeled 
scrambled probe. 
To  further  evaluate  the  possibility  of  protein 
b i n d i n g   t o   t h e   p u t a t i v e   B P 1   b i n d i n g   s i t e ,   E M S A   w a s  
performed using a DIG-labeled 33-mer specific for the 
BP1 binding site in the first intron of BRCA1. Binding 
to  the  DIG-labeled  probe  was  observed  as  a  shifted 
b a n d   i n   p r o t e i n   e x t r a c t s   i s o l a t e d   f r o m   B P 1   o v e r e x-
pressing MCF7 cells (Fig. 2 lane 2). Specificity of pro-
tein binding to the DIG-labeled oligomer was tested 
by competitive inhibition of binding by the addition 
of 50- and 100-fold molar excess of unlabeled specific 
probe  (Fig.  2  lanes  3  and  4).  When  50-fold  molar 
excess unlabeled probe specific for BP1 binding was 
a d d e d   t o   t h e   p r o t e i n   e x t r a c t ,   b i n d i n g   t o   t h e  
DIG-labeled oligomer was reduced by more than half. 
T h e   a d d i t i o n   o f   1 0 0 -fold  molar  excess  of  unlabeled 
s p e c i f i c   p r o b e   r e d u c e d   b i n d i n g   t o   t h e   D I G -labeled 
probe  even  further,  almost  entirely  eliminating  the 
observed  DNA  shift.  Furthermore,  the  addition  of 
100-fold  molar  excess  of  an  unlabeled 
non-competitive  oligomer  to  the  protein  extract  did 
n o t   a f f e c t   t h e   g e l   m o b i l i t y   s h i f t   o f   t h e   D I G -labeled 
p r o b e   ( F i g .   2   l a n e   5 ) .   T o   t e s t   t h e   s p e c i f i c i t y   o f   t h e  
binding, super shift assay with addition of BP1 anti-
b o d y   w a s   p e r f o r m e d   a n d   a   s u p e r   s h i f t e d   b a n d   w a s  
observed (data not shown). 
Overexpression of BP1 in breast cancer cells 
down-regulates BRCA1 expression  
To  verify  BP1  expression  represses  BRCA1  in 
breast cancer cells, real-time RT-PCR was performed 
to  quantitatively  determine  the  transcription  of  BP1 
and  BRCA1  mRNA  levels  in  BP1-overexpressing 
MCF7 cell lines compared to vector controls (Fig. 3A), 
as well as in transiently transfected BT-20 and SKBR3 
cell lines (Fig. 3B). Real-t i m e   P C R   r e a c t i o n s   w e r e   p e r-
formed  in  duplicate  three  times  and  normalized 
a g a i n s t   1 8 S   r R N A   e x p r e s s i o n .  F o r   B P 1 ,   t h e   n o r m a l i z e d 
expression levels for BP1-overexpressing lines O1, O2, 
and O4 were 94.6, 60.0, and 85.7. Vector control lines 
V1 and V2 exhibited levels of 46.0 and 41.8 for an av-
erage of 43.9. BP1 overexpressors, therefore, had le-
v e l s   o f   B P 1   m R N A   e x p r e s s i o n   1 . 4   t o   2 . 2   fold greater 
on average compared to vector controls. For  BRCA1, 
the  normalized  expression  levels  for  vector  control 
c e l l   l i n e s   V 1   a n d   V 2   w e r e   1 0 0 . 0   a n d   8 9 . 0   f o r   a n   a v e r a g e  
of 94.5. Expression levels for overexpressing lines O1, 
O2, and O4 were 74.0, 71.6, and  63.4,  a  decrease  of 
21.7%, 24.2%, and 32.9% respectively relative to vector 
controls. In transiently transfected BT-20 and SKBR3 
breast cancer cells, the expression of BP1were 2.1 and 
1 . 6   f o l d   h i g h e r   r e s p e c t i v e l y   c o m p a r e d   t o   t h e i r   v e c t o r  
controls,  while BRCA1 were down-regulated  by  2.1 
a n d   1 . 7   f o l d   r e s p e c t i v e l y   ( F i g .   3 B ) .   T h e   m R N A   e x-
p r e s s i o n   o f   B P 1   a n d   B R C A 1   w e r e   c o n s i s t e n t l y   i n-
verse-correlated.  
1           2          3         4          5
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Shifted Band
No protein
BP1 protein
50x cold probe
100x cold probe
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Figure  3.  Real-time  RT-PCR  analysis  of  BP1  and 
BRCA1  expression.  Relative  BP1  and BRCA1  mRNA 
expression levels were quantified by real-time RT-PCR and 
normalized against 18S expression levels. Data are the mean 
± standard error for three experiments for BRCA1 and BP1 
with duplicates each. Student’s t test was done for statistical 
significance  analysis  (*P  <  0.05).  A.  Stable  MCF7  BP1 
overexpressors (O1, O2, and O4) vs. vector controls (V1 
and V2). B. Transient BP1 overexpressor (BT-20/BP1) vs. 
vector control (BT-20/V); and transient BP1 overexpressor 
(SKBR3/BP1) vs. vector control (SKBR3/V). C. T47D cells 
treated with BP1 siRNA target T1 and T2 respectively 
comparing non-targeting (NT) and no siRNA controls. D. 
MDA-MB-231 cells treated with BP1 siRNA target T1 and 
T2  respectively  comparing  non-targeting  (NT)  and  no 
siRNA controls. 
 
BP1 siRNA knock-down in breast cancer cells 
up-regulates BRCA1 expression  
T o   v e r i f y   i f   B P 1   s i R N A   k n o c k -down can poten-
tially  activate  BRCA1  expression,  we  transiently 
transfected T47D and MDA-MB-231 cells respectively 
w i t h   B P 1   s i R N A   t a r g e t s   a n d   c o n t r o l s .   Real-time PCR 
reactions were performed in duplicate three times and 
normalized  against  18S  rRNA  expression.  The  nor-
malized values for the expression of BP1 and BRCA1 
f o r   t h e   f o l l o w i n g   t r a n s f e c t i o n s :   T 1 ,   T 2 ,   n o n -targetting 
( N T )   a n d   n o   s i R N A   c o n t r o l   w e r e   s h o w n   f o r   T 4 7 D  
(Figure 3C), and MDA-MB-2 3 1   ( F i g u r e   3 D ) .   B o t h   T 1  
a n d   T 2   s i R N A   k n o c k e d   d o w n   B P 1   e x p r e s s i o n   b y   m o r e  
t h a n   2   f o l d ,   w h i l e   B R C A 1   e x p r e s s i o n   i n c r e a s e d   b y  
2.5-3   f o l d .   T h e   p u r p o s e   o f   N T   w a s   t o   e n s u r e   t h a t   t h e  
B P 1   k n o c k d o w n   i s   s p e c i f i c   b y   i t s   t a r g e t s ,   n o t   b y   r a n-
dom siRNA targets.  
 
 
Figure 4. W e s t e r n   b l o t   a n a l y s i s   o f   B P 1   a n d   B R C A 1  
protein  levels.  Whole-cell extracts from MCF7 vector 
c o n t r o l s   ( V 1   a n d   V 2 )   a n d   B P 1   o v e r e x p r e s s o r s   ( O 1 ,   O 2 ,   a n d  
O4) were analyzed by Western blotting using antibodies for 
BP1 or BRCA1 (4A). Protein expression levels were nor-
malized against β-actin. BRCA1 protein expression is de-
c r e a s e d   b y   7 2 -79% in BP1 overexpressors relative to vector 
controls. Relative BP1 and BRCA1 expression levels are 
presented  based  on  results  from  one  experiment  each 
(4B.). 
 
We  next  questioned  whether  altered  BRCA1 
mRNA expression in BP1 overexpressors was asso-
ciated with altered BRCA1 expression at the protein 
level.  Western  blot  analysis  was  performed  using 
whole-cell  extracts  isolated  from M C F 7   B P 1   o v e r e x-
pressing  and  vector  control  cell lines (Fig. 4).  Band 
intensity  for  BP1  and  BRCA1  was  quantified  and 
normalized against actin using NIH ImageJ (Version 
1.43).  Relative  protein  expression  levels  for  BP1 
overexpressing cell lines O1, O2, and O4 were 100.0, 
82.5, and 87.4, while expressio n   l e v e l s   f o r   v e c t o r   c o n-
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t r o l   c e l l   l i n e s   V 1   a n d   V 2   w e r e   4 2 . 9   a n d   4 2 . 9 .  BP1 pro-
tein levels, therefore, were on average increased by 2.0 
to 2.3 fold in BP1 overexpressing cell lines compared 
to  vector  controls.  F o r   B R C A 1 ,   t h e   n o r m a l i z e d   e x-
pression levels for v e c t o r   c o n t r o l   c e l l   l i n e s   V 1   a n d   V 2  
were 100.0 and 93.5 for an average of 96.8, while BP1 
overexpressing lines O1, O2, and O4 were 27.0, 25.0, 
and  19.9,  a  decrease  of  72.1%,  74.2%,  and  79.4%  re-
spectively relative to vector controls. 
Inverse correlation between BP1 and BRCA1 
immunostaining in patient tissue.  
Immunostaining was also performed using an-
t i b o d i e s   f o r   B P 1   a n d   B R C A 1   o n   c o n s e c u t i v e   h u m a n  
b r e a s t   t u m o r   t i s s u e   s e c t i o n s   ( n = 1 5 )   w i t h   c o -existing 
normal,  hyperplasia,  in  situ,  and  invasive  compo-
nents,  and  distinct  BRCA1  and  BP1  immu-
no-reactivity was seen in a subset of epithelial cells. 
The  expression  of  BRCA1  and  BP1  appeared  to  be 
inversely correlated. Distinct BRCA1 expression was 
consistently  seen  in  most  normal  and  hyperplastic 
cells  (Fig.  5A  and  5B),  whereas  its  expression  ap-
p e a r e d   t o   d e c r e a s e   w i t h   t u m o r   p r o g r e s s i o n ,   w i t h   n o  
o r   s u b s t a n t i a l l y   r e d u c e d   e xpression in most in situ and 
invasive tumor cells (Fig. 5C and 5D). In  contrast, no 
d i s t i n c t   B P 1   e x p r e s s i o n   w a s   s e e n   i n   m o s t   n o r m a l   a n d  
hyperplastic cells  (Fig.  5A and 5B), whereas intense 
and uniform BP1 immunoreactivity was consistently 
present in most in situ and invasive cancer cells (Fig. 
5C and 5D).  
 
Figure 5. Expression status of BP1 and BRCA1 in normal and different breast lesions. Consecutive tissue 
sections from human breast tumors (n=15) with co-existing normal, pre-invasive, and invasive components were immu-
nost a i n e d   u s i n g   a n t i b o d i e s   f o r   B P 1   a n d   B R C A 1 ,   a n d   t h e   e x p r e s s i o n   s t a t u s   o f   B P 1   a n d   B R C A 1   a t   t h e   s a me cell population in 
two different sections was compared. Distinct BRCA1 expression but no distinct BP1 expression was consistently seen in 
m o s t   n o r m a l   ( A) and hyperplastic (B)   c e l l s .  B R C A 1   e x p r e s s i o n   a p p e a r e d   t o   d e c r e a s e   w i t h   t h e   e x t e n t   o f   t u m o r   p r ogression, 
with no or substantially reduced expression in most in situ (C) and invasive (D) tumor cells, while intense and uniform BP1 
immunoreactivity was consistently present. Int. J. Biol. Sci. 2010, 6 
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Discussion 
These results help elucidate the molecular  me-
c h a n i s m s   c o n t r o l l i n g   B R C A 1   e x p r e s s i o n   a n d   p r o v i d e  
an updated picture of the genomic organization of the 
BRCA1 promoter region (Fig. 6). BRCA1 transcription 
i s   d e p e n d e n t   o n   a   b i -directional  promoter  located 
within  a  229  base  pair  intergenic  region  between 
B R C A 1   a n d   a   n e i g h b o r i n g   u n r e l a t e d   g e n e   c a l l e d  
NBR2 [36]. Deletion analysis identified a minimal 56 
base pair EcoRI-HaeIII fragment within the intergenic 
region that retained bi-directional promoter activity. 
In addition, a number of sequence elements have been 
identified  that  potentially  regulate  the  BRCA1  pro-
moter. These include a CREB/ATF-1  site  that  likely 
functions as a transcriptional enhancer [10] [37] and 
a n   E 2 F   s i t e   that  potentially  mediates  estro-
gen-dependent  BRCA1  expression  [38].  Regulatory 
elements  located  within  noncoding  regions  of  the 
BRCA1 gene have also been identified. Suen and Goss 
used deletion analysis to localize a 36 base pair re-
pressor element located more than 500 base pairs into 
the first intron of BRCA1 [39]. The region was found 
t o   c o n t a i n   s e v e r a l   G A -rich sequences that may  serve 
as potential binding sites for the ets or Sp1 families of 
transcription  factors.  More  recently,  cross-species 
comparative sequence analysis of human and mouse 
intronic sequences in the BRCA1 gene identified two 
evolutionarily  conserved  noncoding  sequences  in 
i n t r o n   2 ,   5   k b   d o w n s t r e a m   o f   t h e   B R C A 1   p r o m o t e r  
[40]. The finding that BP1 binds to the first intron of 
BRCA1, therefore, is consistent with the results of the 
previou s   t w o   s t u d i e s   t h a t   i d e n t i f i e d   r e g u l a t o r y   e l e-
ments  located  within  noncoding  regions  of  the 
BRCA1 gene. 
The results presented in this paper for the first 
time  suggest  that  BP1  binds  to  the  first  intron  of 
BRCA1  and  negatively  regulates  its  transcription. 
Since  BRCA1  is  developmentally  expressed  and  is 
involved in cell proliferation and differentiation, it is 
logical that its transcription is in part regulated by a 
homeoprotein such as BP1.  
 
 
Figure 6. Genomic organization of   t h e   B R C A 1   p r o m o t e r   r e g i o n   a n d   l o c a l i z a t i o n   o f   t h e   B P 1   c o n s e n s u s  
binding site. The top part of the diagram shows the organization of introns and exons for the BRCA1 and NBR2 genes 
( m a r k e d   b y   o p e n   a n d   g r a y   b o x e s   r e s p e c t i v e l y ) .  T r a n s c r i p t i o n   o f   B R C A 1   a n d   i t s neighboring gene NBR2 proceeds toward the 
right and left sides respectively. A 56 base pair minimal region located within a 229 base pair intergenic region between 
BRCA1 and NBR2 functions as a minimal bi-directional promoter for the two divergently transcribed genes. The bottom 
part of the diagram shows the region from the beginning of intron 1 to the end of exon 2 of BRCA1. Numbering of nuc-
leotide positions is the same as for GenBank accession number U37574. A putative repressor region located between 
nucleotides 2255 and 2337 is marked by a purple box and contains several GA-rich sequences that may serve as potential 
binding sites for the ets or Sp1 families of transcription factors. A yellow box represents exon 2 from nucleotide positions 
2857 to 2956. BP1 is shown as a green oval binding to the consensus sequence ATATATATG within the first intron of 
BRCA1 from nucleotide positions 2830 to 2838, which is -47 to -39 base pairs upstream of the translational star t   s i t e   i n   e x o n  
2 (marked by a yellow star).  Int. J. Biol. Sci. 2010, 6 
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Conclusions 
Our results demonstrated that B P 1 ,   a n   i s o f o r m   o f  
DLX4 homeoprotein, negatively regulates the expres-
sion of BRCA1 through binding to its intron, which 
suggests  that  overe x p r e s s i o n   o f   B P 1   m i g h t   b e   a   p o-
tential  initiator  to  inactivate  BRCA1.  Therefore,  tar-
g e t i n g   B P 1   m a y   p r o v i d e   a   n e w   a v e n u e   f o r   b r e a s t  
cancer prevention and treatment. 
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